Skip to content

Is there a generic Ozempic? What FDA records show in 2026

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

No. Novo Nordisk says no FDA-approved generic of semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, exists [2], and the key patent the FDA lists for it runs to December 2031 [7]. Anything sold online as a cheap copy is either compounded or counterfeit, and the FDA says neither is a generic.

Who says there is no generic

Novo Nordisk, the maker, says it is the only company in the US with FDA-approved semaglutide and that no generic versions exist [1]. Its professional site puts it more exactly: there are currently no FDA-approved generic versions of any semaglutide medicine [2]. An older FDA page in Spanish, last updated in 2024, also says no approved generic versions exist [3].

A generic, in the US sense, is an FDA-approved copy with the same active-ingredient formula as the brand, rated by the FDA as just as safe and effective [4]. Until the FDA approves one for semaglutide, there is nothing to buy under that name.

What the FDA’s patent records show

The FDA publishes the patents and exclusivity periods drugmakers list for each approved drug in the Orange Book. Two things block generics there. Patents are granted by the patent office; exclusivity is a separate delay on approving competitors that comes with an FDA approval [5]. A new patent normally runs 20 years from its filing date, though other factors can change that [6].

Product What the Orange Book lists
Ozempic injection A drug-substance patent expiring 12/05/2031 [7]; a use patent to 06/21/2033 [8]; an exclusivity to 01/28/2028 [9]
Wegovy injection The same drug-substance patent, to 12/05/2031 [11]; a product patent to 02/17/2041 [12]; exclusivities to 03/08/2027 and 08/15/2028 [13]
Wegovy tablets The same drug-substance patent, to 12/05/2031 [14]

The “DS” flag in the Orange Book marks a patent that claims the drug substance itself. That is the one shared by every semaglutide product above, and it runs to December 2031 [7]. The Ozempic exclusivity to January 2028 is tied to one newer use: the FDA’s code list describes it as lowering the risk of kidney decline and heart-related death [10].

Do not read these dates as a launch date for a generic. The FDA itself warns that an Orange Book listing is not a reliable guide to which patent claims a maker can assert [15]. A listed expiry date is a record of what the maker filed, not a promised launch date for a generic.

Compounded semaglutide is not a generic

The FDA says compounded drugs are not FDA-approved and are not the same as generics, which are [16]. It also says companies may not advertise compounded products as generic versions of, or the same as, approved drugs [17]. Some products sold online use salt forms such as semaglutide sodium or acetate, which the FDA calls different active ingredients from the approved drugs [18].

Counterfeits are a separate problem. In late 2025 the FDA seized dozens of fake Ozempic 1 mg pens that had reached the legitimate supply chain [19]. Its advice is to get Ozempic only with a valid prescription from a state-licensed pharmacy and to check the pen before use [20]. More warning signs are on fake and unapproved GLP-1 products.

The cheapest real semaglutide today

Without a generic, the lowest prices come from Novo Nordisk’s own self-pay offers. The starting dose of the Ozempic pill, a diabetes medicine, is $149 for a 30-tablet bottle [21]. The Wegovy pill for weight loss also starts at $149 a bottle [22]. Higher doses cost more; see Ozempic savings, Wegovy savings and GLP-1 prices without insurance. Which medicine fits your condition is a question for your prescriber.

A generic application with tentative approval

The FDA’s Drugs@FDA database lists a generic application for semaglutide injection from Apotex, numbered ANDA 220314 [23], with a tentative approval dated April 7, 2026 [24]. The FDA explains that a tentative approval means a generic is ready before the brand’s patents or exclusivities run out: final approval waits until those issues are resolved, and in the meantime the company may not market the product [25]. So a generic is in the pipeline, but none can be sold in the US yet.

Sources

  1. We are the only company in the US with FDA-approved medications containing semaglutide. No generic versions of semaglutide currently exist. ozempic.com, read Sep 27, 2026.
  2. There are currently no FDA-approved generic versions of medicines containing semaglutide available. novomedlink.com, read Sep 27, 2026.
  3. Los tres medicamentos sólo están disponibles con receta médica, y no existen versiones genéricas aprobadas. fda.gov, read Sep 27, 2026.
  4. A prescription drug that has the same active-ingredient formula as a brand-name drug. Generic drugs usually cost less than brand-name drugs. The Food and Drug Administration (FDA) rates these drugs to be as safe and effective as brand-name drugs. healthcare.gov, read Sep 27, 2026.
  5. Exclusivity refers to certain delays and prohibitions on approval of competitor drugs available under the statute that attach upon approval of a drug or of certain supplements. fda.gov, read Sep 27, 2026.
  6. Currently, the term of a new patent is 20 years from the date on which the application for the patent was filed in the United States. Many other factors can affect the duration of a patent. fda.gov, read Sep 27, 2026.
  7. 001 8129343 12/05/2031 DS DP U-2202 12/20/2017 accessdata.fda.gov, read Sep 27, 2026.
  8. 001 10335462 06/21/2033 U-2580 07/25/2019 accessdata.fda.gov, read Sep 27, 2026.
  9. Exclusivity Data Product No Exclusivity Code Exclusivity Expiration 001 I-961 01/28/2028 accessdata.fda.gov, read Sep 27, 2026.
  10. I-961 TO REDUCE THE RISK OF SUSTAINED ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) DECLINE, END-STAGE KIDNEY DISEASE, AND CARDIOVASCULAR DEATH accessdata.fda.gov, read Sep 27, 2026.
  11. 001 8129343 12/05/2031 DS DP 06/30/2021 accessdata.fda.gov, read Sep 27, 2026.
  12. 001 11318191 02/17/2041 DP U-3162 06/29/2022 accessdata.fda.gov, read Sep 27, 2026.
  13. 001 I-935 03/08/2027 001 I-973 08/15/2028 accessdata.fda.gov, read Sep 27, 2026.
  14. 001 8129343 12/05/2031 DS DP 02/04/2026 accessdata.fda.gov, read Sep 27, 2026.
  15. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner. accessdata.fda.gov, read Sep 27, 2026.
  16. Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed. Compounded drugs are also not the same as generic drugs, which are FDA-approved. fda.gov, read Sep 27, 2026.
  17. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. fda.gov, read Sep 27, 2026.
  18. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. fda.gov, read Sep 27, 2026.
  19. FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were distributed illegally outside of Novo Nordisk's authorized supply chain. fda.gov, read Sep 27, 2026.
  20. Patients should only obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product before using for any signs of counterfeiting. fda.gov, read Sep 27, 2026.
  21. Ozempic® 1.5 mg 30 tablets bottle $149.00 novocare.com, read Sep 27, 2026.
  22. 00169-4415-31 Wegovy ® 1.5 mg 30 tablets Bottle $149.00 $298.00 $447.00 novocare.com, read Sep 27, 2026.
  23. Abbreviated New Drug Application (ANDA) : 220314 Company: APOTEX INC accessdata.fda.gov, read Sep 28, 2026.
  24. 04/07/2026 ORIG-1 Tentative Approval STANDARD accessdata.fda.gov, read Sep 28, 2026.
  25. If a generic drug product is ready for approval before the expiration of any patents or exclusivities accorded to the reference listed drug product, FDA issues a tentative approval letter to the applicant. The tentative approval letter details the circumstances associated with the tentative approval. FDA delays final approval of the generic drug product until all patent or exclusivity issues have been resolved. A tentative approval does not allow the applicant to market the generic drug product. fda.gov, read Sep 28, 2026.